| Name | Title | Contact Details |
|---|
Care Rx Corporate Office is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MRI Interventions, Inc. is a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Since our inception in 1998, we have focused on research and product development in the field of interventional MRI. From 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling MRI-guided interventions and to build an intellectual property position. In 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. We have two product platforms. Our ClearPoint® system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. Our ClearTrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. Both systems utilize intra-procedural magnetic resonance imaging to guide the procedures. Both systems are designed to work in a hospital’s existing MRI suite. Our products are designed to provide a new, minimally invasive surgical approach for the benefit of large patient populations. Our ClearPoint system is designed to enable the delivery of therapies to treat certain neurological diseases. Our ClearTrace system is designed to deliver therapies to treat certain cardiac diseases. We believe that our two product platforms, subject to appropriate regulatory clearance and approval, will provide better patient outcomes, enable physicians and hospitals to treat more patients, and reduce costs to the healthcare system.
Formed by revenue cycle industry leaders, Currance is a Rev-Cycle Performance solutions company focused on empowering community providers, physician practices and healthcare systems to achieve and sustain yield performance improvement. Currance`s strategy of Performance Partnering supports your own team by offering everything needed to drive yield performance: an intelligent technology platform that integrates with existing systems, tailored solutions, and professional services for operationalizing the technology and sustaining exceptional results. The Currance approach encompasses best-in-class knowledge of revenue cycle management, proprietary technologies, and the proven ability to engage, train, and mentor employees, adding value to clients` organizations. We embrace a mindset rooted in science and operational experience, enabling highly efficient processes and precise workflow design that improve profitability and help build patient-centered, high-performing organizations.
Avanti Hospitals currently owns and operates four acute care hospitals: East Los Angeles Doctors Hospital, Memorial Hospital of Gardena, Community Hospital of Huntington Park, and Coast Plaza Hospital, all located near Los Angeles, California. Our mission is to provide affordable, high quality healthcare services to our community with consistency and compassion. Avanti is committed to cooperating with and supporting the long-term needs and objectives of each community we serve. We understand the impact we have on our communities and the potential to improve overall health. We have worked hard to establish a reputation of quality and trust in our communities, including local physicians and governments. At each of our hospitals, we seek to implement community support through a variety of initiatives that are specific to each individual community. With nearly 2,000 employees and over 775 physicians, the Avanti team is committed to delivering the highest quality care to our patients through a broad range of medical services. We also continue to add new programs and technology to meet the meet the growing needs of the communities we serve.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.